Exhibitions remain one of the most powerful ways for pharmaceutical and life sciences organisations to connect, educate and ...

Pfizer has announced results from its phase 3 BASIS study of Hympavzi (marstacimab), demonstrating its success in reducing ...

Kite, a Gilead Company, has presented new findings demonstrating the safety, efficacy and quality of life benefits offered by ...

Embodiment Perhaps more philosophical, but none-the less highly relevant, is the concept of embodiment – the experience of ...

New results from the phase 1 VNA-318-01 human study have shown favourable safety and tolerability, with the data showing that ...

As global pricing reforms squeeze margins and reshapes supply chains, manufacturers can restore confidence through smarter ...

AI-generated personas can assist in brainstorming with a hypothetical HCP, validate test queries for medical information ...

Our 2025 EcoVadis reassessment has resulted in a score of 75/100, allowing us to maintain our silver medal status for the 3rd year running. This achievement places us in the top 15% of all companies ...

The agreement states that the UK will pay more for medicines through the NHS, in exchange for an agreement that US import ...

Some bad decisions are the result of biases, of which there are various flavours, such as confirmation, anchoring and recency ...

Eisai has submitted a new drug application to Japan’s Pharmaceuticals and Medical Devices Agency for a subcutaneous ...

Roche has received clearance from the US Food and Drug Administration (FDA) for its point of care diagnostic test for ...